Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 129

Results For "Head"

1552 News Found

Dr. Reddy's set to acquire Nimbus Health
News | February 03, 2022

Dr. Reddy's set to acquire Nimbus Health

The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients


Budget 22-23: Healthcare sector applauds focus on mental health
News | February 01, 2022

Budget 22-23: Healthcare sector applauds focus on mental health

A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook


USFDA approves Genentech’s Vabysmo to treat causes of vision loss
Drug Approval | January 31, 2022

USFDA approves Genentech’s Vabysmo to treat causes of vision loss

Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need


ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct
News | January 29, 2022

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct


Minimizing API losses critical to responsible pharma manufacturing
News | January 27, 2022

Minimizing API losses critical to responsible pharma manufacturing

Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases


Intellect closes US $10 m Series A to scale mental healthcare across Asia
Startup | January 26, 2022

Intellect closes US $10 m Series A to scale mental healthcare across Asia

The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners


Roche’s Evrysdi granted USFDA priority review for treatment of spinal muscular atrophy
Drug Approval | January 26, 2022

Roche’s Evrysdi granted USFDA priority review for treatment of spinal muscular atrophy

Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date


Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
News | January 26, 2022

Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.

Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021


USFDA rejects Merck’s gefapixant; gain approval in Japan
News | January 25, 2022

USFDA rejects Merck’s gefapixant; gain approval in Japan

Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant


Sanofi signs as first partner of Protas
Biotech | January 25, 2022

Sanofi signs as first partner of Protas

The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases